HAEM5:Langerhans cell histiocytosis: Difference between revisions
| [checked revision] | [checked revision] |
Bailey.Glen (talk | contribs) table test |
Bailey.Glen (talk | contribs) No edit summary |
||
| Line 137: | Line 137: | ||
</blockquote> | </blockquote> | ||
==Individual Region Genomic Gain/Loss/LOH== | ==Individual Region Genomic Gain/Loss/LOH== | ||
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene rearrangements. Details on clinical significance such as prognosis and other important information can be provided in the notes section. Can refer to CGC workgroup tables as linked on the homepage if applicable. Please include references throughout the table. Do not delete the table.'') </span> | |||
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene rearrangements. Details on clinical significance such as prognosis and other important information can be provided in the notes section. Can refer to CGC workgroup tables as linked on the homepage if applicable. Please include references throughout the table. Do not delete the table.'') </span> | |||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
| Line 146: | Line 145: | ||
!'''Clinical Relevance Details/Other Notes''' | !'''Clinical Relevance Details/Other Notes''' | ||
|- | |- | ||
|<span class="blue-text">EXAMPLE:</span>7 | |<span class="blue-text">EXAMPLE:</span> | ||
7 | |||
|<span class="blue-text">EXAMPLE:</span> Loss | |<span class="blue-text">EXAMPLE:</span> Loss | ||
|<span class="blue-text">EXAMPLE:</span>chr7 | |<span class="blue-text">EXAMPLE:</span> | ||
|<span class="blue-text">EXAMPLE:</span>Unknown | chr7 | ||
|<span class="blue-text">EXAMPLE:</span> | |||
Unknown | |||
|<span class="blue-text">EXAMPLE:</span> D, P | |<span class="blue-text">EXAMPLE:</span> D, P | ||
|<span class="blue-text">EXAMPLE:</span> No | |<span class="blue-text">EXAMPLE:</span> No | ||
|<span class="blue-text">EXAMPLE:</span>Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add references). | |<span class="blue-text">EXAMPLE:</span> | ||
Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add references). | |||
|- | |- | ||
|<span class="blue-text">EXAMPLE:</span>8 | |<span class="blue-text">EXAMPLE:</span> | ||
8 | |||
|<span class="blue-text">EXAMPLE:</span> Gain | |<span class="blue-text">EXAMPLE:</span> Gain | ||
|<span class="blue-text">EXAMPLE:</span>chr8 | |<span class="blue-text">EXAMPLE:</span> | ||
|<span class="blue-text">EXAMPLE:</span>Unknown | chr8 | ||
|<span class="blue-text">EXAMPLE:</span> | |||
Unknown | |||
|<span class="blue-text">EXAMPLE:</span> D, P | |<span class="blue-text">EXAMPLE:</span> D, P | ||
| | | | ||
|<span class="blue-text">EXAMPLE:</span>Common recurrent secondary finding for t(8;21) (add references). | |<span class="blue-text">EXAMPLE:</span> | ||
Common recurrent secondary finding for t(8;21) (add references). | |||
|- | |- | ||
|<span class="blue-text">EXAMPLE:</span>17 | |<span class="blue-text">EXAMPLE:</span> | ||
17 | |||
|<span class="blue-text">EXAMPLE:</span> Amp | |<span class="blue-text">EXAMPLE:</span> Amp | ||
|<span class="blue-text">EXAMPLE:</span>17q12; chr17:39,700,064-39,728,658 [hg38; 28.6 kb] | |<span class="blue-text">EXAMPLE:</span> | ||
|<span class="blue-text">EXAMPLE:</span>''ERBB2'' | 17q12; chr17:39,700,064-39,728,658 [hg38; 28.6 kb] | ||
|<span class="blue-text">EXAMPLE:</span> | |||
''ERBB2'' | |||
|<span class="blue-text">EXAMPLE:</span> D, P, T | |<span class="blue-text">EXAMPLE:</span> D, P, T | ||
| | | | ||
|<span class="blue-text">EXAMPLE:</span>Amplification of ''ERBB2'' is associated with HER2 overexpression in HER2 positive breast cancer (add references). Add criteria for how amplification is defined. | |<span class="blue-text">EXAMPLE:</span> | ||
Amplification of ''ERBB2'' is associated with HER2 overexpression in HER2 positive breast cancer (add references). Add criteria for how amplification is defined. | |||
|- | |- | ||
| | | | ||
| Line 177: | Line 188: | ||
| | | | ||
| | | | ||
|} | |} | ||
==Characteristic Chromosomal or Other Global Mutational Patterns== | ==Characteristic Chromosomal or Other Global Mutational Patterns== | ||